benzo-lipoxin A4 methyl ester

Benzo-lipoxin A4 methyl ester is a synthetic, metabolically stable analog of the endogenous specialized pro-resolving mediator (SPM) Lipoxin A4 (LXA4). Naturally occurring LXA4 is rapidly inactivated by 15-hydroxyprostaglandin dehydrogenase (15-PGDH); however, the benzo-analog incorporates a benzene ring into the carbon chain, which confers resistance to metabolic degradation while preserving biological potency. The molecule acts as a high-affinity agonist of the Formyl peptide receptor 2 (FPR2), also known as the ALX receptor. Its mechanism involves the active resolution of inflammation by inhibiting the recruitment and activation of neutrophils (PMNs) and promoting the non-phlogistic phagocytosis of apoptotic cells by macrophages. The methyl ester modification serves as a prodrug to enhance cellular permeability and bioavailability, which is subsequently hydrolyzed by intracellular esterases to the active acid form. It is primarily used as a research tool and has shown efficacy in preclinical models of inflammatory diseases such as periodontitis, asthma, and acute lung injury.

Brand names

ClinRinse-1ClinRinse1ClinRinse 1

Other names

benzo-lipoxin A4 methyl esterbenzo-LXA4 methyl esterbenzo-LXA-4 methyl esterbenzo-LXA 4 methyl esterbenzo-LXA4 methyl ester prodrugbenzo-LXA-4 methyl ester prodrugbenzo-LXA 4 methyl ester prodrug